Andrew Teasdale

Andrew Teasdale

Andrew Teasdale

Principal Consultant

ATCMC Solutions Limited
Nelson Labs Europe
The United Kingdom
Nelson Labs

Dr. Andrew Teasdale is an expert in the field of mutagenic impurities other impurity related matters. He has advanced a number of key scientific advancements in the control of impurities as the inventor of the purge factor concept and the instigator of the development of Elemental Impurities database for excipients.
With over 50 scientific papers, he has also written 3 books focused on impurity related matters including most recently. Mutagenic Impurities – Strategies for Identification and Control Second Edition. Editor A Teasdale. Publisher Wiley. ISBN 978-1-119-55121-8.
As of since October 1st of 2025, Nelson Labs Europe announced the appointment of Dr. Andrew Teasdale as Principal Consultant.

Speaked About
Genotoxic Impurities Nitrosamines & Beyond
December 2, 2026
Explore 2026 EMA trends, AI risk mapping, ppb-level LC-MS/MS, and advanced mitigation for nitrosamines and genotoxic impurity compliance.
Upcoming

DAY 1: December 2nd, 2026

SESSION: The Nitrosamines journey – current status and future expectations / hopes

►  The good news – progress in terms of.

◆  Understanding what is and isn’t a risk.

◆  Control options in both API and DP.

◆  Analysis of Nitrosamines.

◆  Adoption of the Less than Lifetime principle.

►  The challenges remaining

◆  Other risk factors – Nox and complexity.

◆  The CMC rabbit – how many more times will he come to our rescue ?

◆  Is safety science going to provide the answers we need?

◆  Another N-Nitroso species – are we making the same mistakes again?

Genotoxic Impurities Nitrosamines
December 4, 2025
Two-day virtual event focused on the latest developments, technical challenges in genotoxic impurity control. [Recording: 14 video sessions].
Expired

DAY 1: December 4th, 2025

SESSION: N-Nitrosamines – Past, present and future a personal reflection

◆  Current situation – level of risk.

◆  Risk Assessment – what are the main areas of concern / risk.

◆  What we have learnt from scientific Collaboration control and analysis.

◆  Safety Science and Acceptable Intakes – strengths and limitations of CPCA and EAT.

◆  What next for Nitrosamines – What would success look like.

Speaker Details
  • Profession
    Principal Consultant
  • Company
    ATCMC Solutions Limited
  • Address
    Research and Development | Pharmaceutical Development Macclesfield, Cheshire, SK10 2NA
Speaker Details
  • Profession
    Principal Consultant
  • Company
    ATCMC Solutions Limited
  • Address
    Research and Development | Pharmaceutical Development Macclesfield, Cheshire, SK10 2NA